Venous thromboembolism includes deep vein thrombosis and its complication, pulmonary embolism. Plasma from 12% to 20% of venous thromboembolism patients is resistant to the anticoagulant effect of activated protein C (APC resistance). Essentially all patients with hereditary APC resistance have a single nucleotide mutation of the coagulation factor V gene (F5rs6025), which encodes for an arginine (R) to glutamine (Q) substitution at position 506 of the factor V protein (FV R506Q). The factor V Leiden (R506Q) gene mutation test is a direct mutation analysis of patient blood leukocyte genomic DNA. Recommend the coagulation-based activated protein C (APC)-resistance ratio (mixing with factor V-deficient plasma) as the initial screening assay for APC-resistance. Depending on the assay system, the APC-resistance ratio may be indeterminate for patients with a lupus anticoagulant or extremely high heparin levels.
No special preparation is needed for Factor V Leiden Mutation Detection Mutation Analysis Blood. Inform your doctor if you are on any medications or have any underlying medical conditions or allergies before undergoing Factor V Leiden Mutation Detection Mutation Analysis Blood. Your doctor depending on your condition will give specific instructions.
|UNISEX||All age groups||Factor V Leiden - Mutation is present in positive cases|